成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> ACS Applied Electronic Materials >>article
ACS Applied Electronic Materials

ACS Applied Electronic Materials

IF: 4.29
Download PDF

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

Published:14 July 2020 DOI: 10.3390/jcm9072225 PMID: 32674280
Noemi Lois, Evie Gardner, Margaret McFarland, David Armstrong, Christine McNally, Nuala Jane Lavery, Christina Campbell, Rita I Kirk, Daiva Bajorunas, Ann Dunne, Anthony Cerami, Michael Brines

Abstract

Purpose: Evaluating the effects of cibinetide in diabetic macular edema (DME).

Methods: Phase 2 trial. Na?ve patients with >400 μm central retinal thickness (CRT) DME in one/both eyes were recruited (May 2016-April 2017) at the Belfast Health and Social Care Trust. The study eye was that with best vision and lowest CRT. Patients self-administered cibinetide 4 mg/day subcutaneously for 12 weeks. Primary and secondary outcomes: mean change from baseline to week 12 in best corrected visual acuity (BCVA), CRT, central retinal sensitivity, tear production, patient-reported outcomes, adverse events and antibodies to cibinetide. Descriptive statistics were used; exploratory analyses focused on non-study eyes, diabetic control, serum cytokines and albuminuria.

Results: Nine patients were recruited; eight completed the study. There was no improvement in mean change baseline-week 12 in BCVA (-2.9 + 5.0), CRT (10 + 94.6 microns), central retinal sensitivity (-0.53 + 1.9 dB) or tear production (-0.13 + 7.7 mm), but there was an improvement in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) composite scores (2.7 + 3.1). Some participants experienced improvements in CRT, tear production, diabetic control and albuminuria. No serious adverse events/reactions or anti-cibinetide antibodies were seen.

Conclusions: The cibinetide 12-week course was safe. Improvements in NEI VFQ-25 scores, CRT, tear production, diabetic control and albuminuria, observed in some participants, warrant further investigation.

Trial registration: EudraCT number: 2015-001940-12. ISRCTN16962255-registration date 25.06.15.

Substances (1)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Cibinetide 1208243-50-8 C51H84N16O21 115 suppliers Inquiry

Similar articles

IF:16.4

Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results.

Accounts of Chemical Research Argyrios Chronopoulos,?Panagiotis Chronopoulos,etc Published: 4 September 2022
IF:1.9

Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate.

Acta Anaesthesiologica Scandinavica J Kanto, U Klotz,etc Published: 1 February 1988
IF:12.7

Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.

ACS Central Science De-Shen Wang, Ming-Tao Hu,etc Published: 1 April 2021